Jupiter Life Line Hospitals Reports Q1 FY27 Results as it Outlines Major Expansion Strategy
Jupiter Life Line Hospitals Limited has reported its consolidated financial results for the first quarter of the fiscal year 2027 (Q1FY27), while simultaneously detailing an aggressive expansion plan aimed at scaling its bed capacity from 1,700 to 2,900. The company provided insights into operational performance and strategic investments supporting future growth.Consolidated Financial Performance Highlights
The consolidated Profit & Loss statement shows key movement across major revenue streams and costs for Q1FY27 compared to previous periods.In terms of profitability metrics:
- Revenue from Operations stood at 392.6 Rs Crs, marking a 16.2% increase year-over-year (YoY). Total Income was 411.0 Rs Crs, up 16.4% YoY.
- Gross Profit reached 331.0 Rs Crs, maintaining a Gross Profit Margin of 80.5%.
- EBITDA for the quarter was recorded at 79.3 Rs Crs, which saw a slight 1.1% increase compared to Q1FY26. This figure is impacted by an operational loss of 9.5 cr and an additional 9.4 cr from Dombivli Hospital during its initial ramp-up phase.
- PAT (Profit After Tax) was 37.5 Rs Crs, representing a -14.7% decrease compared to Q1FY26.
Key financial data from the consolidated statement is presented below:
| Profit and Loss (in Rs. Crs) | Q1FY27 | Q1FY26 | YoY | Q4FY26 | QoQ | FY26 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 392.6 | 337.9 | 16.2% | 371.7 | 5.6% | 1,435.6 |
| Total Income | 411.0 | 352.9 | 16.4% | 387.8 | 6.0% | 1,499.8 |
| Gross Profit | 331.0 | 282.2 | 17.3% | 314.1 | 5.4% | 1,212.5 |
| EBITDA | 79.3 | 78.4 | 1.1% | 89.2 | -11.1% | 343.3 |
| EBIT | 52.9 | 57.2 | -7.5% | 65.9 | -19.8% | 255.6 |
| PAT | 37.5 | 43.9 | -14.7% | 50.2 | -25.3% | 194.2 |
Management Commentary and Operational Updates
Dr. Ankit Thakker, MD & CEO, commented that the Dombivli hospital completed its first full quarter of operations, noting steadily increasing occupancy supported by increased patient footfall and service expansions. The EBITDA loss from Dombivli, amounting to 9.5 crore in this quarter, was noted to be consistent with internal projections and earlier guidance.The company continues to add new specialties and strengthen its consultant base as part of a phased development strategy, while initiating the process for insurance empanelment to boost patient inflows in subsequent quarters. Established hospitals are maintaining healthy occupancy levels, providing a stable operational foundation.
Progress is continuing on the Pune South, Mira Road, and BKC projects.
Strategic Focus: Expanding Bed Capacity
The hospital group has an ambitious plan focused on scaling its bed capacity from 1,700 to 2,900 beds through strategic expansion. The growth strategy emphasizes phased commissioning to optimize capital deployment and focuses on acquiring a strategic land bank in high-demand micro markets.Details of the ongoing projects are provided below:
| Hospitals | Bed Capacity | Capex/Bed (Excl. Land) (Rs in cr) | Remarks |
|---|---|---|---|
| Dombivli | 500 | 1.0 | Phase-wise commissioning is underway, with approximately 200 beds operational and fit-outs completed for an additional 100 beds. |
| Pune II | 500 | 1.2 | Currently under construction. |
| Mira - Bhayandar | 300 | 1.3 | The project is currently in the conceptualization and planning stage. |
| BKC | 400 | 1.5 | Project documentation and registration are ongoing. |
The company maintains that strong operating leverage can be achieved from its consolidated scale, supported by a funding philosophy based on internal accruals, with a conversion rate averaging approximately 75 to 80% over the last five years supporting planned expansion capex.
JLHL Stock Price Movement
Shares of Jupiter Life Line Hospitals Limited shed 0.72% today, settling at ₹331.50 after declining by ₹2.40 from the previous close. The stock traded within an intraday range defined by a low of ₹325.00 and a high of ₹334.50, with 167,868 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: